Improving Outcomes for Patients With CML With TKIs: FAQ Podcast
Listen to leukemia experts Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer audience questions from live CCO Webinars on optimizing TKI treatments for patients with chronic-phase chronic myeloid leukemia (CML).
Decera Clinical Education Oncology Podcast
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer questions focused on the optimal selection and management of tyrosine kinase inhibitor (TKI) therapy in patients with CML, with topics including:
- Frontline Management of Chronic-Phase CML
- Selection of TKI Based on Goal of Treatment-Free Remission
- Changing TKIs due to Intolerance: Second-line Therapy and Toxicity Management
- Changing TKIs due to CML Progression: Second-line Therapy and Future Options
Presenters:
Prof. Dr. med Tim Henrik Brümmendorf
Head
Department of Hematology, Oncology, Hematostaseology, and Stem Cell Transplantation
University Hospital Aachen, RWTH Aachen
Aachen, Germany
Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia, USA
Carlo Gambacorti-Passerini, MD
Professor, Hematology
University Milano Bicocca
Director, Hematology
San Gerardo Hospital
Monza, Italy
Content based on an online CME program supported by an educational grant from Pfizer Inc.
Link to full program, including associated downloadable slidesets:
https://bit.ly/30P8Uaf
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.